The 10 Big Discoveries
Discovery 1 | Food allergy may be a protective alarm set too high
The body has natural defenses that assess what is safe to take in and what should be avoided. FASI-supported research is revealing how food allergy may draw on this protective system. Animal studies show that an allergic response can activate immune defenses and signal the brain to avoid a food. These findings support a broader idea: food allergy may be an exaggerated defense against danger, with the alarm set too high or directed at a harmless food protein.
Scientists can investigate how the alarm is triggered, which signals strengthen or restrain it, and why it responds to harmless food. This opens new directions for research into changing the response at its source.
Understanding the allergic alarm could lead to treatments that make the body less likely to react to a harmless food.
This is a scientific framework, not a complete explanation for every person or form of food allergy. Key evidence comes from animal studies.
Food allergy crosses the boundaries between systems
The next discoveries show how the response can begin at a barrier, travel through nerves and immune signals, and influence what happens elsewhere in the body.
Discovery 2 | Signals in the skin can help set allergy in motion
The skin is an active meeting place for immune cells, sensory nerves, and the outside world. FASI-supported research is revealing how signals there can help set allergic responses in motion. In animal studies, immune cells primed sensory nerves to respond more strongly to allergens, substances such as food proteins that can trigger allergic reactions. Separate research found that skin damage could prime an immune response to food entering through the gut, even when that food had never touched the skin. This preparation to react is called allergic sensitization.
These studies identify distinct ways that signals in the skin can shape allergic responses, including responses to substances encountered far from the skin itself.
Tracing early signals between skin, nerves, and immune cells could reveal ways to prevent food allergy before it takes hold.
Much of this work comes from animal studies. Sensitization does not always lead to symptoms, and how these pathways contribute to food allergy in people still needs to be established.
Others apply the brake.
Discovery 3 | Nerves can help direct T cells
Nerves carry signals such as itch and pain. They can also help direct the immune response itself. Work led by FASI investigators Vijay Kuchroo and Isaac Chiu shows how neurons, or nerve cells, influence T cells, immune cells that help guide the body’s response to a threat. In experimental studies, nerve signals including CGRP changed how T cells developed and behaved. Related work showed how sensory nerves regulate T cells in the gut, including regulatory T cells that help keep immune activity in balance.
The nervous system does not just react. It helps instruct immunity. These studies give researchers specific signals to investigate as potential treatment targets, opening new ways to test whether changing those signals can change the immune response.
Changing the signals that guide T cells could offer new ways to prevent immune cells from driving an allergic response.
These studies establish how nerve signals can shape immunity in experimental systems. Whether targeting them can safely prevent food-allergic reactions in people remains to be established.
Discovery 4 | Nerve signals can turn allergic inflammation up or down
FASI-supported researchers identified nerve signals that give the same type of immune cell opposing instructions. These cells, called ILC2s, help drive allergic inflammation. In experimental systems, a nerve signal called NMU activated these cells and intensified inflammation. Another signal, CGRP, could restrain their activity. Like an accelerator and a brake, these signals help control the strength of the response. An imbalance may make inflammation harder to control.
The same type of immune cell can receive signals from nerves that increase or limit its activity. Understanding both helps researchers investigate more precise control of inflammation.
These findings could guide treatments that calm allergic inflammation while preserving the immune defenses people need to stay healthy.
The effects of these signals depend on the cells and setting. Restoring balance is a treatment goal to investigate; these findings do not yet establish a proven therapy.
Discovery 5 | A cell-by-cell map reveals the gut’s nervous system
The gut has its own extensive nervous system. FASI-supported teams built a detailed map of its nerve-cell types using human samples and animal studies, distinguishing cells across different parts of the intestine. This cellular atlas gives researchers a reference for telling those cells apart. Follow-up animal studies examined how gut nerve cells respond to microbes, allergy, and infection. Related work traced signals in both directions between gut nerves and immune cells.
Researchers can identify which nerve-cell types and signals change in a particular condition, then investigate their role in disease and healthy gut function.
This map could help scientists find ways to treat food allergy while protecting the gut’s ability to function normally.
The atlas includes human samples, but much of the follow-up evidence comes from animal studies. It is a research resource, not a treatment or clinical test.
Discovery 6 | Reducing IgE signals may shape protection during treatment
IgE is an antibody, an immune protein, that helps trigger immediate allergic reactions. Researchers studied what happens when its signals are reduced before and early in oral immunotherapy (OIT), a treatment using regular, measured doses of an allergenic food under medical direction. Blood samples from people initially given the IgE-blocking medicine omalizumab showed stronger antibody activity that blocked allergic responses than samples from the placebo group. In laboratory tests, those antibodies more effectively restrained basophils, immune cells involved in reactions.
These findings give researchers a way to investigate how reducing IgE signals early in treatment may shape the development of protective antibodies during OIT.
These findings could guide better treatment timing and combinations, helping oral immunotherapy build stronger protection against allergic reactions.
This analysis used samples from 34 people who completed OIT in a small clinical trial. Larger studies are needed before it can guide treatment decisions. It did not establish protection after OIT ends.
Discovery 7 | Some antibodies can help block an allergic response
Not every antibody makes food allergy worse. IgE can prepare mast cells and basophils, immune cells involved in allergic reactions, to respond to an allergen. FASI-supported studies show how other antibodies, called IgG and IgA, can help limit that response. Some block an allergen from reaching IgE. IgG can also send signals that restrain the reacting cells. This helps explain how a person may gain protection during oral immunotherapy even while an allergy test still detects IgE.
Researchers can look beyond IgE levels to investigate what protective antibodies do and where they act. This gives a fuller picture of how the body may resist an allergic reaction.
Studying protective antibodies could reveal how well treatment is protecting a patient, even when an allergy test still detects IgE.
Laboratory and animal studies show these mechanisms. The presence of IgG or IgA does not guarantee lasting tolerance, the ability to tolerate a food after treatment ends. Effects depend on the antibody, its target, and where it acts.
What suggests protection may last?
Discovery 8 | Signals in the gut can amplify a food reaction
Two animal studies revealed how the gut can help a food reaction escalate. Chemical signals called leukotrienes allowed more intact food allergen, protein that had not been broken down, to cross the intestinal lining. Related research showed that leukotrienes released by intestinal mast cells, immune cells involved in allergy, helped drive anaphylaxis, a severe, potentially life-threatening reaction.
Researchers can investigate how allergen movement across the gut lining and local chemical signals intensify a reaction. These findings identify additional points where a future treatment might interrupt that escalation.
These findings point toward future treatments that could keep a food reaction from escalating into a life-threatening emergency.
The findings come from animal studies and need to be tested in people. They do not yet provide a treatment or a way to predict an individual’s reaction severity.
Discovery 9 | How antibodies work may help explain protection after treatment
After peanut oral immunotherapy (OIT), some people maintained protection during a break from treatment while others did not. FASI-supported researchers found clues in IgG4, a type of antibody. Antibodies linked to more sustained protection recognized particular shapes on Ara h 2, an important peanut allergen. These antibodies more effectively blocked the allergen from activating IgE-driven reactions in immune cells. What the antibodies could do mattered beyond how many were present.
Researchers can examine where antibodies attach to an allergen and how effectively they block a reaction, alongside measuring their quantity. This creates new ways to investigate why protection lasts longer in some people.
For patients, these antibody clues could help reveal whether protection is likely to continue after peanut oral immunotherapy ends.
One study assessed protection after one to three months without treatment. These are research clues, not proof of lifelong protection or a validated test for deciding when someone can stop OIT.
Discovery 10 | T cells respond differently to the same treatment
Why can two people receive the same food allergy treatment and have very different outcomes? One clue may be in their T cells. FASI-supported researchers developed a way to track groups of related T cells, called clones, that recognize peanut during oral immunotherapy (OIT). T cells help direct the immune response. In people with better outcomes, OIT more strongly quieted a specific group of allergy-driving T cells. In those with less successful outcomes, broader inflammatory activity persisted.
Researchers can look beyond average T-cell activity to identify which groups respond to treatment and which remain active. This gives scientists a more precise way to investigate why outcomes differ from person to person.
These findings could help scientists tailor treatment to a person’s immune response, including people who gain less protection from oral immunotherapy.
The clinical study included 12 participants, three of whom received placebo. These findings do not yet provide a validated test to predict someone’s response or guide their care. Larger studies are needed.